STAAR/$STAA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About STAAR

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Ticker

$STAA
Primary listing

Industry

Health Care Equipment & Supplies

Employees

1,157

ISIN

US8523123052

STAAR Metrics

BasicAdvanced
$828M
-
-$1.44
0.66
-

What the Analysts think about STAAR

Analyst ratings (Buy, Hold, Sell) for STAAR stock.

Bulls say / Bears say

STAAR Surgical's recent leadership transition, with Stephen C. Farrell appointed as President and CEO, brings over 20 years of experience in global healthcare businesses, potentially driving strategic growth and innovation. (staar.com)
The company's strong liquidity position, with $230.5 million in cash and investments as of fiscal year-end 2024, provides a solid foundation for future investments and operational stability. (investors.staar.com)
Despite challenges in the Chinese market, STAAR Surgical achieved a 13% increase in ICL sales excluding China in fiscal 2024, indicating robust demand and growth potential in other regions. (investors.staar.com)
STAAR Surgical reported a net loss of $20.2 million for fiscal year 2024, a significant decline from the previous year's net income of $21.3 million, raising concerns about profitability. (investors.staar.com)
The company's heavy reliance on the Chinese market, which experienced a significant decline in revenue, poses a risk if the market does not recover as anticipated. (investors.staar.com)
Multiple law firms have initiated investigations into potential violations of federal securities laws by STAAR Surgical, which could lead to legal challenges and financial penalties. (financialmodelingprep.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

STAAR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

STAAR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STAA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs